Maria Dolores Sanchez-Nio

List of Publications by Citations

184 papers	31,965 citations	53 h-index	178 g-index
211 ext. papers	40,633 ext. citations	9.5 avg, IF	5.94 L-index

#	Paper	IF	Citations
184	Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet, The*, **2016**, 388, 1545-1602	40	3801
183	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet, The*, **2016**, 388, 1459-1544	40	3525
182	Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet, The*, **2018**, 392, 1736-1788	40	2850
181	Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet, The*, **2017**, 390, 1151-1210	40	2542
180	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet, The*, **2016**, 388, 1659-1724	40	2431
179	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet, The*, **2018**, 392, 1923-1994	40	1964
178	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet, The*, **2017**, 390, 1345-1422	40	1378
177	Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet, The*, **2018**, 392, 1859-1922	40	1283
176	Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet, The*, **2016**, 388, 1603-1658	40	1216
175	Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet, The*, **2018**, 392, 1015-1035	40	1171
174	Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet, The*, **2017**, 390, 1260-1344	40	1152
173	Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet, The*, **2018**, 392, 1684-1735	40	483
172	Global, regional, and national levels of maternal mortality, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet, The*, **2016**, 388, 1775-1812	40	476
171	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet, The*, **2017**, 390, 1084-1150	40	421
170	Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet, The*, **2016**, 388, 1725-1774	40	413
169	NF-kappaB in renal inflammation. *Journal of the American Society of Nephrology: JASN*, **2010**, 21, 1254-62	12.7	385
168	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. *Lancet, The*, **2018**, 391, 2236-2271	40	381

167	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990-2015: a novel analysis from the Global Burden of Disease Study 2015. *Lancet, The*, **2017**, 390, 231-266	40	352
166	The inflammatory cytokines TWEAK and TNF reduce renal klotho expression through NFB. *Journal of the American Society of Nephrology: JASN*, **2011**, 22, 1315-25	12.7	257
165	Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet, The*, **2018**, 392, 2091-2138	40	210
164	Ferroptosis, but Not Necroptosis, Is Important in Nephrotoxic Folic Acid-Induced AKI. *Journal of the American Society of Nephrology: JASN*, **2017**, 28, 218-229	12.7	199
163	Population and fertility by age and sex for 195 countries and territories, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet, The*, **2018**, 392, 1995-2051	40	189
162	Tenofovir nephrotoxicity: 2011 update. *AIDS Research and Treatment*, **2011**, 2011, 354908	2.3	168
161	The cytokine TWEAK modulates renal tubulointerstitial inflammation. *Journal of the American Society of Nephrology: JASN*, **2008**, 19, 695-703	12.7	145
160	Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. *Nephrology Dialysis Transplantation*, **2011**, 26, 1797-802	4.3	138
159	Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy. *American Journal of Physiology - Renal Physiology*, **2012**, 302, F647-57	4.3	120
158	Cytokine cooperation in renal tubular cell injury: the role of TWEAK. *Kidney International*, **2006**, 70, 1750-8	9.9	117
157	Unilateral ureteral obstruction: beyond obstruction. *International Urology and Nephrology*, **2014**, 46, 765-76	2.5	116
156	2017 update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms and therapeutic implications. *Oncotarget*, **2017**, 8, 18456-18485	3.3	84
155	Fibrosis: a key feature of Fabry disease with potential therapeutic implications. *Orphanet Journal of Rare Diseases*, **2013**, 8, 116	4.2	82
154	The MIF receptor CD74 in diabetic podocyte injury. *Journal of the American Society of Nephrology: JASN*, **2009**, 20, 353-62	12.7	81
153	Myocardial fibrosis and apoptosis, but not inflammation, are present in long-term experimental diabetes. *American Journal of Physiology - Heart and Circulatory Physiology*, **2009**, 297, H2109-19	5.2	79
152	TWEAK and the progression of renal disease: clinical translation. *Nephrology Dialysis Transplantation*, **2014**, 29 Suppl 1, i54-i62	4.3	78
151	MO017THERAPEUTICAL POTENTIAL OF ENZYME REPLACEMENT: NEW INSIGHTS AND PERSPECTIVES IN HUMAN ENDOTHELIAL CELLS TREATED WITH CHLOROQUINE. *Nephrology Dialysis Transplantation*, **2021**, 36,	4.3	78
150	Lyso-Gb3 activates Notch1 in human podocytes. *Human Molecular Genetics*, **2015**, 24, 5720-32	5.6	77

149	TWEAK activates the non-canonical NFkappaB pathway in murine renal tubular cells: modulation of CCL21. *PLoS ONE*, **2010**, 5, e8955	3.7	77
148	TWEAK, a multifunctional cytokine in kidney injury. *Kidney International*, **2011**, 80, 708-18	9.9	76
147	Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. *Lancet Diabetes and Endocrinology,the*, **2020**, 8, 301-312	18.1	75
146	The inflammatory cytokine TWEAK decreases PGC-1 expression and mitochondrial function in acute kidney injury. *Kidney International*, **2016**, 89, 399-410	9.9	74
145	Tweak induces proliferation in renal tubular epithelium: a role in uninephrectomy induced renal hyperplasia. *Journal of Cellular and Molecular Medicine*, **2009**, 13, 3329-42	5.6	74
144	The location of splenic NKT cells favours their rapid activation by blood-borne antigen. *EMBO Journal*, **2012**, 31, 2378-90	13	73
143	Atherosclerosis in Chronic Kidney Disease: More, Less, or Just Different?. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2019**, 39, 1938-1966	9.4	69
142	p-cresyl sulphate has pro-inflammatory and cytotoxic actions on human proximal tubular epithelial cells. *Nephrology Dialysis Transplantation*, **2014**, 29, 56-64	4.3	65
141	TWEAK and RIPK1 mediate a second wave of cell death during AKI. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, 4182-4187	11.5	64
140	Mitochondria-targeted therapies for acute kidney injury. *Expert Reviews in Molecular Medicine*, **2014**, 16, e13	6.7	64
139	Histone lysine crotonylation during acute kidney injury in mice. *DMM Disease Models and Mechanisms*, **2016**, 9, 633-45	4.1	64
138	BASP1 promotes apoptosis in diabetic nephropathy. *Journal of the American Society of Nephrology: JASN*, **2010**, 21, 610-21	12.7	63
137	TNF superfamily: a growing saga of kidney injury modulators. *Mediators of Inflammation*, **2010**, 2010,	4.3	63
136	Klotho, phosphate and inflammation/ageing in chronic kidney disease. *Nephrology Dialysis Transplantation*, **2012**, 27 Suppl 4, iv6-10	4.3	63
135	Impact of Altered Intestinal Microbiota on Chronic Kidney Disease Progression. *Toxins*, **2018**, 10,	4.9	62
134	Targeting epigenetic DNA and histone modifications to treat kidney disease. *Nephrology Dialysis Transplantation*, **2018**, 33, 1875-1886	4.3	58
133	The burden of disease in Spain: Results from the Global Burden of Disease 2016. *Medicina Clínica*, **2018**, 151, 171-190	1	55
132	TWEAK (tumor necrosis factor-like weak inducer of apoptosis) activates CXCL16 expression during renal tubulointerstitial inflammation. *Kidney International*, **2012**, 81, 1098-107	9.9	55

131	Translational value of animal models of kidney failure. *European Journal of Pharmacology*, **2015**, 759, 205-20	5.3	52
130	Targeting inflammation in diabetic kidney disease: early clinical trials. *Expert Opinion on Investigational Drugs*, **2016**, 25, 1045-58	5.9	52
129	Albumin downregulates Klotho in tubular cells. *Nephrology Dialysis Transplantation*, **2018**, 33, 1712-1722	4.3	50
128	CXCL16 in kidney and cardiovascular injury. *Cytokine and Growth Factor Reviews*, **2014**, 25, 317-25	17.9	49
127	Nutrients Turned into Toxins: Microbiota Modulation of Nutrient Properties in Chronic Kidney Disease. *Nutrients*, **2017**, 9,	6.7	48
126	HSP27/HSPB1 as an adaptive podocyte antiapoptotic protein activated by high glucose and angiotensin II. *Laboratory Investigation*, **2012**, 92, 32-45	5.9	47
125	Deferasirox nephrotoxicity-the knowns and unknowns. *Nature Reviews Nephrology*, **2014**, 10, 574-86	14.9	45
124	Horizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System Blockade. *Journal of Clinical Medicine*, **2015**, 4, 1325-47	5.1	44
123	Inflammatory Cytokines as Uremic Toxins: "Ni Son Todos Los Que Estan, Ni Estan Todos Los Que Son". *Toxins*, **2017**, 9,	4.9	43
122	The Role of PGC-1□and Mitochondrial Biogenesis in Kidney Diseases. *Biomolecules*, **2020**, 10,	5.9	42
121	New paradigms in cell death in human diabetic nephropathy. *Kidney International*, **2010**, 78, 737-44	9.9	42
120	Considering TWEAK as a target for therapy in renal and vascular injury. *Cytokine and Growth Factor Reviews*, **2009**, 20, 251-8	17.9	42
119	PGC-1□deficiency causes spontaneous kidney inflammation and increases the severity of nephrotoxic AKI. *Journal of Pathology*, **2019**, 249, 65-78	9.4	41
118	Fn14 in podocytes and proteinuric kidney disease. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2013**, 1832, 2232-43	6.9	41
117	Osteoprotegerin in exosome-like vesicles from human cultured tubular cells and urine. *PLoS ONE*, **2013**, 8, e72387	3.7	40
116	Downregulation of kidney protective factors by inflammation: role of transcription factors and epigenetic mechanisms. *American Journal of Physiology - Renal Physiology*, **2016**, 311, F1329-F1340	4.3	40
115	Association of kidney fibrosis with urinary peptides: a path towards non-invasive liquid biopsies?. *Scientific Reports*, **2017**, 7, 16915	4.9	39
114	MXRA5 is a TGF-□-regulated human protein with anti-inflammatory and anti-fibrotic properties. *Journal of Cellular and Molecular Medicine*, **2017**, 21, 154-164	5.6	37

113	TWEAK/Fn14 and Non-Canonical NF-kappaB Signaling in Kidney Disease. *Frontiers in Immunology*, **2013**, 4, 447	8.4	37
112	Impaired Vitamin D Signaling in Endothelial Cell Leads to an Enhanced Leukocyte-Endothelium Interplay: Implications for Atherosclerosis Development. *PLoS ONE*, **2015**, 10, e0136863	3.7	37
111	Effects of Pentoxifylline on Soluble Klotho Concentrations and Renal Tubular Cell Expression in Diabetic Kidney Disease. *Diabetes Care*, **2018**, 41, 1817-1820	14.6	36
110	Targeting local vascular and systemic consequences of inflammation on vascular and cardiac valve calcification. *Expert Opinion on Therapeutic Targets*, **2016**, 20, 89-105	6.4	33
109	MIF, CD74 and other partners in kidney disease: tales of a promiscuous couple. *Cytokine and Growth Factor Reviews*, **2013**, 24, 23-40	17.9	32
108	Podocytes are new cellular targets of haemoglobin-mediated renal damage. *Journal of Pathology*, **2018**, 244, 296-310	9.4	32
107	TWEAK favors phosphate-induced calcification of vascular smooth muscle cells through canonical and non-canonical activation of NFB. *Cell Death and Disease*, **2016**, 7, e2305	9.8	31
106	Cardiovascular risk biomarkers in CKD: the inflammation link and the road less traveled. *International Urology and Nephrology*, **2012**, 44, 1731-44	2.3	30
105	Osteoprotegerin and kidney disease. *Journal of Nephrology*, **2014**, 27, 607-17	4.8	29
104	Kidney Injury Marker 1 and Neutrophil Gelatinase-Associated Lipocalin in Chronic Kidney Disease. *Nephron*, **2017**, 136, 263-267	3.3	29
103	Albumin-induced apoptosis of tubular cells is modulated by BASP1. *Cell Death and Disease*, **2015**, 6, e1644	9.8	28
102	Bcl3: a regulator of NF-B inducible by TWEAK in acute kidney injury with anti-inflammatory and antiapoptotic properties in tubular cells. *Experimental and Molecular Medicine*, **2017**, 49, e352	12.8	28
101	A combinatorial approach of Proteomics and Systems Biology in unravelling the mechanisms of acute kidney injury (AKI): involvement of NMDA receptor GRIN1 in murine AKI. *BMC Systems Biology* , **2013**, 7, 110	3.5	28
100	Progress in the development of animal models of acute kidney injury and its impact on drug discovery. *Expert Opinion on Drug Discovery*, **2013**, 8, 879-95	6.2	26
99	The Spanish Society of Nephrology (SENEFRO) commentary to the Spain GBD 2016 report: Keeping chronic kidney disease out of sight of health authorities will only magnify the problem. *Nefrologia*, **2019**, 39, 29-34	1.5	25
98	Urine metabolomics insight into acute kidney injury point to oxidative stress disruptions in energy generation and HS availability. *Journal of Molecular Medicine*, **2017**, 95, 1399-1409	5.5	24
97	Designing drugs that combat kidney damage. *Expert Opinion on Drug Discovery*, **2015**, 10, 541-56	6.2	24
96	The burden of disease in Greece, health loss, risk factors, and health financing, 2000-16: an analysis of the Global Burden of Disease Study 2016. *Lancet Public Health, The*, **2018**, 3, e395-e406	22.4	24

95	Targeting of regulated necrosis in kidney disease. *Nefrologia*, **2018**, 38, 125-135	1.5	23
94	Non-canonical NFB activation promotes chemokine expression in podocytes. *Scientific Reports*, **2016**, 6, 28857	4.9	23
93	Increased urinary osmolyte excretion indicates chronic kidney disease severity and progression rate. *Nephrology Dialysis Transplantation*, **2018**, 33, 2156-2164	4.3	22
92	Out of the TWEAKlight: Elucidating the Role of Fn14 and TWEAK in Acute Kidney Injury. *Seminars in Nephrology*, **2016**, 36, 189-98	4.8	22
91	Mitogen-Activated Protein Kinase 14 Promotes AKI. *Journal of the American Society of Nephrology: JASN*, **2017**, 28, 823-836	12.7	22
90	Lesinurad: what the nephrologist should know. *CKJ: Clinical Kidney Journal*, **2017**, 10, 679-687	4.5	21
89	Next-generation phosphate binders: focus on iron-based binders. *Drugs*, **2014**, 74, 863-77	12.1	20
88	Notch3 and kidney injury: never two without three. *Journal of Pathology*, **2012**, 228, 266-73	9.4	20
87	Tyrphostins as potential therapeutic agents for acute kidney injury. *Current Medicinal Chemistry*, **2010**, 17, 974-86	4.3	20
86	Modulation of renal tubular cell survival: where is the evidence?. *Current Medicinal Chemistry*, **2006**, 13, 449-54	4.3	20
85	Increased urinary CD80 excretion and podocyturia in Fabry disease. *Journal of Translational Medicine*, **2016**, 14, 289	8.5	20
84	Sarcopenia in CKD: a roadmap from basic pathogenetic mechanisms to clinical trials. *CKJ: Clinical Kidney Journal*, **2019**, 12, 110-112	4.5	19
83	NFBiz protein downregulation in acute kidney injury: Modulation of inflammation and survival in tubular cells. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2016**, 1862, 635-646	6.9	19
82	Diabetes mellitus and chronic kidney disease in the Eastern Mediterranean Region: findings from the Global Burden of Disease 2015 study. *International Journal of Public Health*, **2018**, 63, 177-186	4	19
81	Deferasirox-induced iron depletion promotes BclxL downregulation and death of proximal tubular cells. *Scientific Reports*, **2017**, 7, 41510	4.9	17
80	Low dose aspirin increases 15-epi-lipoxin A4 levels in diabetic chronic kidney disease patients. *Prostaglandins Leukotrienes and Essential Fatty Acids*, **2017**, 125, 8-13	2.8	17
79	Epigenetic Modifiers as Potential Therapeutic Targets in Diabetic Kidney Disease. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	17
78	A slit in podocyte death. *Current Medicinal Chemistry*, **2008**, 15, 1645-54	4.3	17

77	3,4-DGE is important for side effects in peritoneal dialysis what about its role in diabetes. *Current Medicinal Chemistry*, **2006**, 13, 2695-702	4.3	17
76	TWEAK promotes peritoneal inflammation. *PLoS ONE*, **2014**, 9, e90399	3.7	17
75	PCSK9 in diabetic kidney disease. *European Journal of Clinical Investigation*, **2016**, 46, 779-86	4.6	16
74	Circulating CXCL16 in Diabetic Kidney Disease. *Kidney and Blood Pressure Research*, **2016**, 41, 663-671	3.1	16
73	Obesity and chronic kidney disease progression-the role of a new adipocytokine: C1q/tumour necrosis factor-related protein-1. *CKJ: Clinical Kidney Journal*, **2019**, 12, 420-426	4.5	16
72	3,4-DGE is cytotoxic and decreases HSP27/HSPB1 in podocytes. *Archives of Toxicology*, **2014**, 88, 597-608	5.8	15
71	Inflammatory cytokines and survival factors from serum modulate tweak-induced apoptosis in PC-3 prostate cancer cells. *PLoS ONE*, **2012**, 7, e47440	3.7	15
70	The demise of calcium-based phosphate binders. *Lancet, The*, **2013**, 382, 1232-4	40	14
69	CD74 in Kidney Disease. *Frontiers in Immunology*, **2015**, 6, 483	8.4	14
68	Diagnosis and treatment of Fabry disease. *Medicina Clínica*, **2017**, 148, 132-138	1	13
67	NIK as a Druggable Mediator of Tissue Injury. *Trends in Molecular Medicine*, **2019**, 25, 341-360	11.5	13
66	Ferroptosis and kidney disease. *Nefrologia*, **2020**, 40, 384-394	1.5	13
65	Translational science in chronic kidney disease. *Clinical Science*, **2017**, 131, 1617-1629	6.5	13
64	The Contribution of Histone Crotonylation to Tissue Health and Disease: Focus on Kidney Health. *Frontiers in Pharmacology*, **2020**, 11, 393	5.6	13
63	Molecular pathways driving omeprazole nephrotoxicity. *Redox Biology*, **2020**, 32, 101464	11.3	12
62	Albuminuria Downregulation of the Anti-Aging Factor Klotho: The Missing Link Potentially Explaining the Association of Pathological Albuminuria with Premature Death. *Advances in Therapy*, **2020**, 37, 62-72	4.1	12
61	Clinical proteomics in kidney disease as an exponential technology: heading towards the disruptive phase. *CKJ: Clinical Kidney Journal*, **2017**, 10, 188-191	4.5	12
60	Macrophages and recently identified forms of cell death. *International Reviews of Immunology*, **2014** , 33, 9-22	4.6	12

59	Paricalcitol for reduction of albuminuria in diabetes. *Lancet, The*, **2011**, 377, 635-6, author reply 636-7	40	12
58	AG490 promotes HIF-1α accumulation by inhibiting its hydroxylation. *Current Medicinal Chemistry*, **2012**, 19, 4014-23	4.3	12
57	Advances in understanding the role of angiotensin-regulated proteins in kidney diseases. *Expert Review of Proteomics*, **2019**, 16, 77-92	4.2	12
56	Loss of NLRP6 expression increases the severity of acute kidney injury. *Nephrology Dialysis Transplantation*, **2020**, 35, 587-598	4.3	12
55	The Spanish Society of Nephrology (SENEFRO) commentary to the Spain GBD 2016 report: Keeping chronic kidney disease out of sight of health authorities will only magnify the problem. *Nefrologia*, **2019**, 39, 29-34	0.4	11
54	Targeting of regulated necrosis in kidney disease. *Nefrologia*, **2018**, 38, 125-135	0.4	11
53	TWEAK increases CD74 expression and sensitizes to DDT proinflammatory actions in tubular cells. *PLoS ONE*, **2018**, 13, e0199391	3.7	11
52	Dietary Care for ADPKD Patients: Current Status and Future Directions. *Nutrients*, **2019**, 11,	6.7	11
51	Is it or is it not a pathogenic mutation? Is it or is it not the podocyte?. *Journal of Nephropathology*, **2012**, 1, 152-4	0.6	11
50	Chronicity following ischaemia-reperfusion injury depends on tubular-macrophage crosstalk involving two tubular cell-derived CSF-1R activators: CSF-1 and IL-34. *Nephrology Dialysis Transplantation*, **2016**, 31, 1409-16	4.3	11
49	MAGE genes in the kidney: identification of MAGED2 as upregulated during kidney injury and in stressed tubular cells. *Nephrology Dialysis Transplantation*, **2019**, 34, 1498-1507	4.3	11
48	MAP3K kinases and kidney injury. *Nefrologia*, **2019**, 39, 568-580	1.5	10
47	Acute kidney injury transcriptomics unveils a relationship between inflammation and ageing. *Nefrologia*, **2012**, 32, 715-23	1.5	10
46	Cell death-based approaches in treatment of the urinary tract-associated diseases: a fight for survival in the killing fields. *Cell Death and Disease*, **2018**, 9, 118	9.8	9
45	Lyso-Gb3 modulates the gut microbiota and decreases butyrate production. *Scientific Reports*, **2019**, 9, 12010	4.9	9
44	TWEAKing renal injury. *Frontiers in Bioscience - Landmark*, **2008**, 13, 580-9	2.8	9
43	Urine proteomics for prediction of disease progression in patients with IgA nephropathy. *Nephrology Dialysis Transplantation*, **2020**,	4.3	9
42	A CLCNKA polymorphism (rs10927887; p.Arg83Gly) previously linked to heart failure is associated with the estimated glomerular filtration rate in the RENASTUR cohort. *Gene*, **2013**, 527, 670-2	3.8	8

41	Peritoneal defence--lessons learned which apply to diabetes complications. *Nephrology Dialysis Transplantation*, **2006**, 21 Suppl 2, ii12-5	4.3	7
40	Chloroquine may induce endothelial injury through lysosomal dysfunction and oxidative stress. *Toxicology and Applied Pharmacology*, **2021**, 414, 115412	4.6	7
39	Urinary Growth Differentiation Factor-15 (GDF15) levels as a biomarker of adverse outcomes and biopsy findings in chronic kidney disease. *Journal of Nephrology*, **2021**, 34, 1819-1832	4.8	7
38	Enzyme replacement therapy dose and Fabry nephropathy. *Nephrology Dialysis Transplantation*, **2018**, 33, 1284-1289	4.3	6
37	Differential effects of oral and intravenous l-carnitine on serum lipids: is the microbiota the answer?. *CKJ: Clinical Kidney Journal*, **2014**, 7, 437-41	4.5	6
36	The meaning of urinary creatinine concentration. *Kidney International*, **2011**, 79, 791	9.9	6
35	Tacrolimus Prevents TWEAK-Induced PLA2R Expression in Cultured Human Podocytes. *Journal of Clinical Medicine*, **2020**, 9,	5.1	6
34	Renin-angiotensin system and inflammation update. *Molecular and Cellular Endocrinology*, **2021**, 529, 111254	4.4	6
33	Podocyturia: why it may have added value in rare diseases. *CKJ: Clinical Kidney Journal*, **2019**, 12, 49-52	4.5	6
32	Ferroptosis and kidney disease. *Nefrologia*, **2020**, 40, 384-394	0.4	5
31	Expression of uPAR in Urinary Podocytes of Patients with Fabry Disease. *International Journal of Nephrology*, **2017**, 2017, 1287289	1.7	5
30	Undetectable serum calcidiol: not everything that glitters is gold. *CKJ: Clinical Kidney Journal*, **2012**, 5, 37-40	4.5	5
29	The human plasma lipidome. *New England Journal of Medicine*, **2012**, 366, 668; author reply 668-9	59.2	5
28	Chronodisruption: A Poorly Recognized Feature of CKD. *Toxins*, **2020**, 12,	4.9	4
27	The location of splenic NKT cells favours their rapid activation by blood-borne antigen. *EMBO Journal*, **2012**, 31, 3029-3030	13	4
26	Design and optimization strategies for the development of new drugs that treat chronic kidney disease. *Expert Opinion on Drug Discovery*, **2020**, 15, 101-115	6.2	4
25	A multicenter blinded preclinical randomized controlled trial on Jak1/2 inhibition in MRL/MpJ-Fas mice with proliferative lupus nephritis predicts low effect size. *Kidney International*, **2021**, 99, 1331-1341	9.9	4
24	Unravelling drug-induced hypertension: molecular mechanisms of aldosterone-independent mineralocorticoid receptor activation by posaconazole. *CKJ: Clinical Kidney Journal*, **2018**, 11, 688-690	4.5	4

23	TWEAK and the kidney: the dual role of a multifunctional cytokine. *Advances in Experimental Medicine and Biology*, **2011**, 691, 323-35	3.6	4
22	QThat Obscure Object of DesireQin systemic lupus erythematosus B-cell activating factor/B-lymphocyte stimulator is targeted both by the immune system and by physicians. *Nephrology Dialysis Transplantation*, **2015**, 30, 394-400	4.3	3
21	Does wealth make health? Cherchez la renal replacement therapy. *CKJ: Clinical Kidney Journal*, **2017** , 10, 45-48	4.5	3
20	Modifiable risk factors for increased arterial stiffness in outpatient nephrology. *PLoS ONE*, **2015**, 10, e0123903	3.7	3
19	Thrombotic microangiopathy: expanding genetic, clinical and therapeutic spectra and the need for worldwide implementation of recent advances. *CKJ: Clinical Kidney Journal*, **2015**, 8, 686-9	4.5	3
18	Identification of a potent endothelium-derived angiogenic factor. *PLoS ONE*, **2013**, 8, e68575	3.7	3
17	Lyso-Gb3 Increases Integrin Gene Expression in Cultured Human Podocytes in Fabry Nephropathy. *Journal of Clinical Medicine*, **2020**, 9,	5.1	3
16	Phosphate, Microbiota and CKD. *Nutrients*, **2021**, 13,	6.7	3
15	MAP3K kinases and kidney injury. *Nefrologia*, **2019**, 39, 568-580	0.4	3
14	Urinary Cyclophilin A as Marker of Tubular Cell Death and Kidney Injury. *Biomedicines*, **2021**, 9,	4.8	3
13	Gender, Albuminuria and Chronic Kidney Disease Progression in Treated Diabetic Kidney Disease. *Journal of Clinical Medicine*, **2020**, 9,	5.1	2
12	Nephrotoxicity **2018**, 169-184		2
11	Growth differentiation factor-15 preserves Klotho expression in acute kidney injury and kidney fibrosis.. *Kidney International*, **2022**,	9.9	2
10	Reply. *Medicina Clnica*, **2017**, 149, 271-272	1	1
9	Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy was underpowered. *Drug Design, Development and Therapy*, **2015**, 9, 5873-4	4.4	1
8	Mitochondria-targeted therapies for acute kidney injury ERRATUM. *Expert Reviews in Molecular Medicine*, **2014**, 16,	6.7	1
7	Growth differentiation factor-15 (GDF-15) and syndecan-1 are potential biomarkers of cardiac and renal involvement in classical Fabry disease under enzyme replacement therapy.. *Kidney and Blood Pressure Research*, **2022**,	3.1	1
6	Enzyme Replacement Therapy for Fabry Disease. *FIRE Forum for International Research in Education*, **2016**, 4, 232640981667942	1.4	1

5	Working towards novel albuminuria endpoints in chronic kidney disease. *Lancet Diabetes and Endocrinology,the*, **2019**, 7, 80-82	18.1	1
4	The new marker YKL-40, a molecule related to inflammation, is associated with cardiovascular events in stable haemodialysis patients. *CKJ: Clinical Kidney Journal*, **2020**, 13, 172-178	4.5	1
3	Diagnosis and treatment of Fabry disease. *Medicina Clínica (English Edition)*, **2017**, 148, 132-138	0.3	0
2	Research update for articles published in EJCI in 2016. *European Journal of Clinical Investigation*, **2018**, 48, e13016	4.6	
1	MP002TUMOR NECROSIS FACTOR-LIKE WEAK INDUCER OF APOPTOSIS FAVORS PHOSPHATE-INDUCED CALCIFICATION OF VASCULAR SMOOTH MUSCLE CELLS. *Nephrology Dialysis Transplantation*, **2016**, 31, i344-i344	4.3	